Although, our results suggest that both colitis and MMR-deficient models are susceptible to accumulate oxidative genetic lesions, antioxidants or molecules that inhibit iNOS reduce polyposis only in colitis models, suggesting that IBD patients might benefit from the use of such compounds. The gene discussed is NOS2; the disease is polyposis.